TEVA PARTNERS SNOW+ROCK FOR HIGH PROFILE AUTUMN PROMOTION
07.02.12
Teva, the speculation footwear brand, (a division of California-based Decker Out of doors Corp) has teamed up with Snow+Rock, the UK’s No. 1 ski clothing and accoutrements retailer, to create a multi-tier consumer promotional struggle for AW11.
The new initiative which will run in-store from November 14th to the end of the year will be fully backed with a London Stealthy advertising campaign and POS support. The campaign itself focuses specifically on Teva’s new winter products: the women’s Tonalea boot and the men’s and women’s Make Pro Winter Mid boots. As an added incentive, purchasers of either dummy receive a free, co-branded, reusable handwarmer which emphasizes the insulated rank of the footwear. Other aspects of the campaign include seeding of merchandise to floor staff, in-store staff training and e-marketing to both Teva and Snow+Finished databases.
Source: Prfire (press release)
NASDAQ Hot Stocks to watch are - ARNA, PSEC, GSM, DECK, ALXN
07.02.12
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) piece change dropped -4.23%, to close at $1.36 and its entire traded volume was 1.40M shares during the last session with the thoroughgoing traded volume of 1.33M shares. ARNA opened at $1.39 and is trading within the sphere of $1.36-$1.42. The 52-week range of the stock is $1.21-$2.38. ARNA’s merchandise capitalization is $198.51M and it has 145.96M outstanding shares.
Arena Pharmaceuticals, Inc. (Arena) is a clinical-originate biopharmaceutical company focused on discovering, developing and commercializing verbal drugs that target G protein-coupled receptors, in four worst therapeutic areas: cardiovascular, central nervous system, demagogic and metabolic diseases. Arena’s advanced slip someone a Mickey Finn candidate is lorcaserin hydrochloride,
Source: Retirement Planning
